We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a … difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive … across- and within-drug heterogeneity. We focus on six drug markets that that were part of the expanded initial complaint and …

of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the … of new drug development, generic entry, and patent length and scope. Optimal policy calls for shorter but broader …